STOCK TITAN

Mersana Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Mersana Therapeutics (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment in areas of high unmet medical need, has announced its participation in two upcoming investor conferences.

Management will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time in a presentation/fireside chat format. Additionally, they will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time.

Both events will be available via live webcasts on the Investors & Media section of Mersana's website (www.mersana.com), with archived replays accessible for approximately 90 days after the events.

Mersana Therapeutics (NASDAQ: MRSN), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di conjugati anticorpo-farmaco (ADC) per il trattamento del cancro in aree con elevate necessità mediche non soddisfatte, ha annunciato la sua partecipazione a due prossime conferenze per investitori.

La direzione presenterà alla 45ª Conferenza Annuale sulla Salute di TD Cowen martedì 4 marzo 2025, alle 13:50 ora orientale, in un formato di presentazione/chat informale. Inoltre, parteciperanno a una chat informale alla Conferenza Globale sulla Salute di Leerink martedì 11 marzo 2025, alle 13:40 ora orientale.

Entrambi gli eventi saranno disponibili tramite webcast dal vivo nella sezione Investitori & Media del sito web di Mersana (www.mersana.com), con repliche archiviate accessibili per circa 90 giorni dopo gli eventi.

Mersana Therapeutics (NASDAQ: MRSN), una compañía biofarmacéutica en etapa clínica enfocada en el desarrollo de conjugados anticuerpo-fármaco (ADC) para el tratamiento del cáncer en áreas de alta necesidad médica no satisfecha, ha anunciado su participación en dos próximas conferencias para inversores.

La dirección presentará en la 45ª Conferencia Anual de Salud de TD Cowen el martes 4 de marzo de 2025, a la 1:50 p.m. hora del Este, en un formato de presentación/chat informal. Además, participarán en una charla informal en la Conferencia Global de Salud de Leerink el martes 11 de marzo de 2025, a la 1:40 p.m. hora del Este.

Ambos eventos estarán disponibles a través de webcasts en vivo en la sección de Inversores y Medios del sitio web de Mersana (www.mersana.com), con repeticiones archivadas accesibles durante aproximadamente 90 días después de los eventos.

Mersana Therapeutics (NASDAQ: MRSN)는 높은 의료 수요가 있는 분야에서 암 치료를 위한 항체-약물 접합체 (ADC) 개발에 집중하는 임상 단계의 생명공학 회사로, 두 개의 투자자 회의에 참여한다고 발표했습니다.

경영진은 2025년 3월 4일 화요일 동부 표준시 오후 1:50에 TD Cowen 제45회 연례 건강 관리 회의에서 발표하며, 프레젠테이션/파이어사이드 챗 형식으로 진행됩니다. 또한, 2025년 3월 11일 화요일 동부 표준시 오후 1:40에 Leerink 글로벌 건강 관리 회의에서 파이어사이드 챗에 참여할 예정입니다.

두 이벤트 모두 Mersana 웹사이트의 투자자 및 미디어 섹션에서 실시간 웹캐스트를 통해 제공되며, 이벤트 후 약 90일 동안 아카이브된 재생이 가능합니다.

Mersana Therapeutics (NASDAQ: MRSN), une entreprise biopharmaceutique en phase clinique axée sur le développement de conjugués anticorps-médicaments (ADC) pour le traitement du cancer dans des domaines à fort besoin médical non satisfait, a annoncé sa participation à deux prochaines conférences pour investisseurs.

La direction présentera à la 45e Conférence Annuelle sur la Santé de TD Cowen le mardi 4 mars 2025, à 13h50 heure de l'Est, dans un format de présentation/chat informel. De plus, ils participeront à un chat informel à la Conférence Mondiale sur la Santé de Leerink le mardi 11 mars 2025, à 13h40 heure de l'Est.

Les deux événements seront disponibles via des webcasts en direct dans la section Investisseurs & Médias du site de Mersana (www.mersana.com), avec des rediffusions archivées accessibles pendant environ 90 jours après les événements.

Mersana Therapeutics (NASDAQ: MRSN), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Antikörper-Wirkstoff-Konjugaten (ADCs) zur Behandlung von Krebs in Bereichen mit hohem ungedecktem medizinischen Bedarf konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt.

Die Geschäftsführung wird am Dienstag, den 4. März 2025, um 13:50 Uhr Eastern Time auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in einem Präsentations-/Fireside-Chat-Format präsentieren. Darüber hinaus werden sie an einem Fireside-Chat auf der Leerink Global Healthcare Conference am Dienstag, den 11. März 2025, um 13:40 Uhr Eastern Time teilnehmen.

Beide Veranstaltungen werden über Live-Webcasts im Bereich Investoren & Medien auf der Website von Mersana (www.mersana.com) verfügbar sein, mit archivierten Wiederholungen, die etwa 90 Tage nach den Veranstaltungen zugänglich sind.

Positive
  • Mersana Therapeutics is actively engaging with the investment community through participation in major healthcare conferences
  • The company is providing transparent access to their presentations through webcasts available on their website
  • Mersana continues to advance its pipeline of antibody-drug conjugates for cancer treatment
  • The company maintains visibility in the biotech investment landscape through these conference appearances
Negative
  • The press release doesn't provide specific updates on clinical trial progress or pipeline developments
  • No financial information or business updates are included in the announcement
  • The announcement is purely about conference participation rather than substantive company developments

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:

  • TD Cowen 45th Annual Health Care Conference
    Format:        Presentation/fireside chat
    Date/Time:  Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time

  • Leerink Global Healthcare Conference
    Format:         Fireside chat
    Date/Time:   Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time

Live webcasts of these events will be available on the Investors & Media section of Mersana’s website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.

Contact:
Jason Fredette
617-498-0020
jason.fredette@mersana.com


FAQ

When will Mersana Therapeutics (MRSN) present at the TD Cowen Healthcare Conference in 2025?

Mersana Therapeutics will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 1:50 p.m. Eastern Time in a presentation/fireside chat format.

What investor conferences is Mersana Therapeutics (MRSN) attending in March 2025?

Mersana Therapeutics is attending two investor conferences in March 2025: the TD Cowen 45th Annual Health Care Conference on March 4 and the Leerink Global Healthcare Conference on March 11.

How can investors access Mersana Therapeutics' (MRSN) presentations at the March 2025 conferences?

Investors can access live webcasts of Mersana's presentations on the Investors & Media section of the company's website at www.mersana.com. Archived replays will be available for approximately 90 days following the events.

What is the focus of Mersana Therapeutics' (MRSN) drug development pipeline?

Mersana Therapeutics focuses on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need.

What time is Mersana Therapeutics' (MRSN) presentation at the Leerink Global Healthcare Conference in 2025?

Mersana Therapeutics will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. Eastern Time.
Mersana Therapeutics Inc

NASDAQ:MRSN

MRSN Rankings

MRSN Latest News

MRSN Stock Data

41.60M
122.75M
1.4%
85.51%
8.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE